" class="no-js "lang="en-US"> Mao Mao - Medtech Alert
Monday, August 18, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Mao Mao

Mao Mao

About Mao Mao

Dr. Mao Mao is Founder & CEO of SeekIn, a blood-based pan cancer early diagnosis company. He is also Adjunct Professor of several universities in Asia. He was Chief Scientific Officer of BGI Genomics and SVP of Wuxi AppTec. He is a strong advocate of genomics and health data sharing.

Specialties: Oncology, genomics, biomarker, molecular diagnostics

Related Story

Diseases

 SeekIn Receives CE Mark Approval for OncoSeek® Multi-Cancer Detection Test | Pharmtech Focus

SeekIn Receives CE Mark Approval for OncoSeek® Multi-Cancer Detection Test

September 13 2022

SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE […]